KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Receivables (2016 - 2025)

Biogen has reported Receivables over the past 17 years, most recently at $1.3 billion for Q4 2025.

  • Quarterly results put Receivables at $1.3 billion for Q4 2025, down 4.44% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (down 4.44% YoY), and the annual figure for FY2025 was $1.3 billion, down 4.44%.
  • Receivables for Q4 2025 was $1.3 billion at Biogen, down from $1.4 billion in the prior quarter.
  • Over the last five years, Receivables for BIIB hit a ceiling of $1.9 billion in Q1 2021 and a floor of $3.9 million in Q1 2025.
  • Median Receivables over the past 5 years was $1.6 billion (2022), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Receivables: crashed 99.55% in 2023 and later surged 8448.42% in 2025.
  • Biogen's Receivables stood at $1.8 billion in 2021, then decreased by 6.97% to $1.7 billion in 2022, then dropped by 2.51% to $1.7 billion in 2023, then decreased by 15.58% to $1.4 billion in 2024, then decreased by 4.44% to $1.3 billion in 2025.
  • The last three reported values for Receivables were $1.3 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.6 billion (Q2 2025) per Business Quant data.